These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30352134)

  • 1. Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.
    de Andrade KC; Frone MN; Wegman-Ostrosky T; Khincha PP; Kim J; Amadou A; Santiago KM; Fortes FP; Lemonnier N; Mirabello L; Stewart DR; Hainaut P; Kowalski LP; Savage SA; Achatz MI
    Hum Mutat; 2019 Jan; 40(1):97-105. PubMed ID: 30352134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.
    de Andrade KC; Mirabello L; Stewart DR; Karlins E; Koster R; Wang M; Gapstur SM; Gaudet MM; Freedman ND; Landi MT; Lemonnier N; Hainaut P; Savage SA; Achatz MI
    Hum Mutat; 2017 Dec; 38(12):1723-1730. PubMed ID: 28861920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
    de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
    HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
    Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of germline TP53 variant classification in children with cancer.
    Tallis E; Scollon S; Ritter DI; Plon SE
    Cancer Genet; 2022 Jun; 264-265():29-32. PubMed ID: 35306447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inherited TP53 Variants and Risk of Prostate Cancer.
    Maxwell KN; Cheng HH; Powers J; Gulati R; Ledet EM; Morrison C; Le A; Hausler R; Stopfer J; Hyman S; Kohlmann W; Naumer A; Vagher J; Greenberg SE; Naylor L; Laurino M; Konnick EQ; Shirts BH; AlDubayan SH; Van Allen EM; Nguyen B; Vijai J; Abida W; Carlo MI; Dubard-Gault M; Lee DJ; Maese LD; Mandelker D; Montgomery B; Morris MJ; Nicolosi P; Nussbaum RL; Schwartz LE; Stadler Z; Garber JE; Offit K; Schiffman JD; Nelson PS; Sartor O; Walsh MF; Pritchard CC
    Eur Urol; 2022 Mar; 81(3):243-250. PubMed ID: 34863587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence.
    Luo M; Wong D; Zelley K; Wu J; Schubert J; Denenberg EH; Fanning EA; Chen J; Gallo D; Golenberg N; Patel M; Conlin LK; Maxwell KN; Wertheim GB; Surrey LF; Zhong Y; Brodeur GM; MacFarland SP; Li MM
    J Natl Cancer Inst; 2024 Aug; 116(8):1356-1365. PubMed ID: 38702830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of novel germline TP53 variants in Swedish families.
    Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
    Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
    BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre.
    Butz H; Bozsik A; Grolmusz V; Szőcs E; Papp J; Patócs A
    Sci Rep; 2023 Aug; 13(1):14259. PubMed ID: 37653074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.
    Amadou A; Achatz MIW; Hainaut P
    Curr Opin Oncol; 2018 Jan; 30(1):23-29. PubMed ID: 29076966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering.
    Soussi T; Leroy B; Devir M; Rosenberg S
    Hum Mutat; 2019 May; 40(5):516-524. PubMed ID: 30720243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
    Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
    Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.